Deregulation of the p14(ARF)/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities

Cancer Research

Volumn 60, Issue 2, 2000, Pages 417-424

  Ichimura, Koichi ^a,b   Bolin, Maria Bondesson ^b,c   Goike, Helena M ^b   Schmidt, Esther E ^a,b   Moshref, Ahmad ^b   Collins, V Peter ^a,b,d  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Division of Molecular Histopathology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROL SYSTEM; CONTROLLED STUDY; DEREGULATION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; BRAIN TUMOR; CELL CYCLE; EXON; GENE SILENCING; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTO ONCOGENE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P53;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL CYCLE; DNA MUTATIONAL ANALYSIS; EXONS; G1 PHASE; GENE SILENCING; GENES, P53; GLIOBLASTOMA; HUMANS; MUTATION; NUCLEAR PROTEINS; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PROTO-ONCOGENES; S PHASE; SEQUENCE DELETION; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034649787     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Reifenberger, G., Reifenberger, J., Ichimura, K., Meltzer, P. S., and Collins, V. P. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res., 54: 4299-4303, 1994.
2. Schmidt, E. E., Ichimura, K., Reifenberger, G., and Collins, V. P. CDKN2 (p16/ MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54: 6321-6324, 1994.
3. Schmidt, E. E., Ichimura, K., Messerle, K. R., Goike, H. M., and Collins, V. P. Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours. Br. J. Cancer, 75: 2-8, 1997.
4. Ueki, K., Ono, Y., Hensen, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.
5. INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene, 13: 1065-1072, 1996.
6. Pines, J. The cell cycle kinases. Semin. Cancer Biol., 5: 305-313, 1994.
7. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
8. Kleihues, P., Burger, P. C., and Scheithauer, B. W. Histological Typing of Tumors of the Central Nervous System, Ed. 2. New York: Springer-Verlag, 1993.
9. Russell, D. S., and Rubinstein, L. J. Tumours of central neuroepithelial origin. In: Pathology of Tumours of the Nervous System, Ed. 5, pp. 83-350. London: Edward Arnold, 1989.
10. Debbas, M., and White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7: 546-554, 1993.
11. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature (Lond.), 365: 349-352, 1993.
12. Wu, X., and Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA, 91: 3602-3606, 1994.
13. Morgenbesser, S. D., Williams, B. O., Jacks, T., and DePinho, R. A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (Lond.), 371: 72-74, 1994.
14. Tsai, K. Y., Hu, Y., Macleod, K. F., Crowley, D., Yamasaki, L., and Jacks, T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell, 2: 293-304, 1998.
15. Prives, C., and Hall, P. A. The p53 pathway. J. Pathol., 187: 112-126, 1999.
16. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
17. Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., and Vogelstein, B. Oncoprolein MDM2 conceals the activation domain of tumour suppressor p53. Nature (Lond.), 362: 857-860, 1993.
18. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature (Lond.), 387: 296-299, 1997.
19. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature (Lond.), 387: 299-303, 1997.
20. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
21. Piette, J., Neel, H., and Marechal, V. Mdm2: keeping p53 under control. Oncogene, 15: 1001-1010, 1997.
22. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell, 83: 993-1000, 1995.
23. INK4A transcript. Cancer Res., 55: 2995-2997, 1995.
24. Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H., Parry, D., Peters, G., and Kamb, A. Complex structure and regulation of the P16 (MTSI) locus. Cancer Res., 55: 2988-2994, 1995.
25. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17: 5001-5014, 1998.
26. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
27. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
28. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA., 95: 8292-8297, 1998.
29. Robertson, K. D., and Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol., 18: 6457-6473, 1998.
30. ARF links the tumour suppressors RB and p53. Nature (Lond.), 395: 124-125, 1998.
31. ARF tumor suppressor. Genes Dev., 12: 2434-2442, 1998.
32. Pan, H., Yin, C., Dyson, N. J., Harlow, E., Yamasaki, L., and Van Dyke, T. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol. Cell, 2: 283-292, 1998.
33. Ichimura, K., Schmidt, E. E., Miyakawa, A., Goike, H. M., and Collins, V. P. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer, 22: 9-15, 1998.
34. Liu, L., Ichimura, K., Pettersson, E. H., and Collins, V. P. Chromosome 7 rearrangements in glioblastomas; loci adjacent to EGFR are independently amplified. J. Neuropathol. Exp. Neurol., 57: 1138-1145, 1998.
35. Ichimura, K., Schmidt, E. E., Yamaguchi, N., James, C. D., and Collins, V. P. A common region of homozygous deletion in malignant human gliomas lies between the IFN-α/ω gene cluster and the D9S171 locus. Cancer Res., 54: 3127-3130, 1994.
36. Hudson, T. J., Stein, L. D., Gerety, S. S., Ma, J., Castle, A. B., Silva, J., Slonim, D. K., Baptista, R., Kruglyak, L., Xu, S. H., Hu, X., Colbert, A., Rosenberg, C., Reeve-Daly, M. P., Rozen, S., Hui, L., Wu, X., Vestergaard, C., Wilson, K., Bae, J., Maitra, S., Ganiatsas, S., Evans, C., DeAngelis, M., Ingalls, K., Nahf, R., Horton, L., Oskin, M., Collymore, A., Ye, W., Kouyoumjian, V., Zernsteva, I., Tarn, J., Devine, R., Courtney, D., Renaud, M., Nguyen, H., O'Connor, T., Fizames, C., Faure, S., Gyapay, G., Dib, C., Morissette, J., Orlin, J., Birren, B., Goodman, N., Weissenbach, J., Hawkins, T., Foote, S., Page, D., and Lander, E. An STS-based map of the human genome, with supplementary data from the Whitehead Institute/MIT Center for Genome Research, Human Genetic Mapping Project, Data Release 11 (October 1996). Science (Washington DC), 270: 1945-1954, 1995.
37. Hamelin, R., Jego, N., Laurent, P. P., Vidaud, M., and Thomas, G. Efficient screening of p53 mutations by denaturing gradient electrophoresis in colorectal tumors. Oncogene, 8: 2213-2220, 1993.
38. Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E. E., and Collins, V. P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res., 53: 2736-2739, 1993.
39. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
40. Hall, M., and Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 68: 67-108, 1996.
41. Momand, J., Jung, D., Wilczynski, S., and Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 26: 3453-3459, 1998.
42. He, J., Allen, J. R., Collins, V. P., Allalunis-Turner, M. J., Godbout, R., Day, R. S., III, and James, C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54: 5804-5807, 1994.
43. Li, H., Lochmuller, H., Yong, V. W., Karpati, G., and Nalbantoglu, J. Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J. Neuropathol. Exp. Neurol., 56: 872-878, 1997.
44. Gomez-Manzano, C., Fueyo, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., and Yung, W. K. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res., 56: 694-699, 1996.
45. Hirama, T., and Koeffler, H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood, 86: 841-854, 1995.
46. Krauter, K., Montgomery, K., Yoon, S. J., LeBlanc-Straceski, J., Renault, B., Marondel, I., Herdman, V., Cupelli, L., Banks, A., and Lieman, J. A second-generation YAC contig map of human chromosome 12. Nature (Lond.), 377 (Suppl): 321-333, 1995.
47. Reifenberger, G., Ichimura, K., Reifenberger, J., Elkahloun, A. G., Meltzer, P. S., and Collins, V. P. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res., 56: 5141-5145, 1996.
48. Sugawa, N., Ekstrand, A. J., James, C. D., and Collins, V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA, 87: 8602-8606, 1990.
49. Reifenberger, J., Ring, G. U., Gies, U., Cobbers, L., Oberstrass, J., An, H. X., Niederacher, D., Wechsler, W., and Reifenberger, G. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol., 55: 822-831, 1996.
50. ARF gene in metastatic melanoma cell lines. Genes Chromosomes Cancer, 23: 273-277, 1998.
51. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. Tumor spectrum in ARF-deficient mice. Cancer Res., 59: 2217-2222, 1999.
52. ARF. Cell, 91: 649-659, 1997.
53. Arap, W., Knudsen, E., Sewell, D. A., Sidransky, D., Wang, J. Y., Huang, H. J., and Cavenee, W. K. Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: evidence for an RB-independent growth suppressive pathway. Oncogene, 15: 2013-2020, 1997.
54. ARF. Proc. Natl. Acad. Sci. USA, 94: 669-673, 1997.
55. INK4a. Exp. Cell Res., 237: 7-13, 1997.
56. Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z. X., Kumar, S., Howley, P. M., and Livingston, D. M. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2: 405-415, 1998.
57. Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., and Perucho, M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science (Washington DC), 275: 967-969, 1997.
58. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
59. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
60. INK4a binding domain of CDK4 in familial melanoma. Nat. Genet., 12: 97-99, 1996.
61. Costello, J. F., Plass, C., Arap, W., Chapman, V. M., Held, W. A., Berger, M. S., Su Huang, H. J., and Cavenee, W. K. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res., 57: 1250-1254, 1997.
62. Antonarakis, S. E. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum. Mutat., 11: 1-3, 1998.